Vera Therapeutics
Sells TRUTAKNA and develops immune-mediated kidney disease treatments.
$33.91
After-hours close−0.26 (−0.76%)
At close$34.17(−1.24%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 112.15%Insiders 3.58%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 71.78M · Float 58.51M · 81.5% free float
Institutions13F, as of Jun 30, 2026
233 holders · 80.51M shares · 33 new positions · 132 increased · 67 reduced · 38 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.75M | 8.01% | +659.7K | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 5.72M | 7.97% | −165.0K | Aug 14, 2026 |
| State Street Corp | 4.15M | 5.78% | +785.1K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 4.01M | 5.59% | −561.1K | Aug 14, 2026 |
| Deep Track Capital, LP | 4.00M | 5.57% | −106.1K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 3.92M | 5.46% | +194.3K | Aug 14, 2026 |
| Kynam Capital Management, LP | 2.89M | 4.03% | −508.2K | Aug 14, 2026 |
| Morgan Stanley | 2.80M | 3.90% | +2.43M | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.90% | 5.61M | 13G | Feb 14, 2025 ↗ |
| T. Rowe Price Associates, Inc. | 6.40% | 4.57M | 13G | May 15, 2026 ↗ |
| State Street Corporation | 5.80% | 4.15M | 13G | Aug 7, 2026 ↗ |
| Deep Track Capital, LP | 5.50% | 3.92M | 13G | Mar 11, 2026 ↗ |
| Kynam Capital Management, LP | 5.37% | 3.43M | 13G | Aug 14, 2025 ↗ |
| Deerfield Mgmt, L.P. | 5.25% | 3.35M | 13G | Jun 11, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Patrick G. Enright | director | 1.80M | 2.51% | Dec 15, 2025 |
| Marshall Fordyce | director, officer: PRESIDENT AND CEO | 235.2K | 0.33% | Aug 12, 2026 |
| Sean Grant | officer: CHIEF FINANCIAL OFFICER | 114.2K | 0.16% | Feb 25, 2026 |
| Joseph R. Young | officer: SVP, FINANCE, CHIEF ACCT OFFCR | 75.8K | 0.11% | Mar 16, 2026 |
| Laurence Matthew Skelton | officer: Chief Commercial Officer | 64.2K | 0.09% | Feb 25, 2026 |
| Robert Brenner | officer: Chief Medical Officer | 50.9K | 0.07% | Feb 25, 2026 |
| Jason S. Carter | officer: Chief Legal Officer | 49.1K | 0.07% | Nov 25, 2025 |
| David Lee Johnson | officer: Chief Operating Officer | 45.7K | 0.06% | Feb 25, 2026 |
| William D. Turner | officer: Chief Regulatory Officer | 45.3K | 0.06% | Feb 25, 2026 |
| Nancy Lee Boman | officer: Chief Regulatory Officer | 45.0K | 0.06% | Aug 5, 2026 |
6 ten-percent owners hold 16.44M shares by Form 4, outside the officers-and-directors figure above · 9 people have not refiled in the last 18 months (8.15M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 12, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 18,500 | $36.74 | 235,244 |
| Jun 23, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 2 lots | 18,500 | $37.93 | 235,244 |
| Jul 7, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 4 lots | 46,250 | $42.30 | 235,244 |
| Apr 14, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale · 3 lots | 22,951 | $44.05 | 235,244 |
| Feb 23, 2026 | Laurence Matthew Skeltonofficer: Chief Commercial Officer | Sale | 1,582 | $41.98 | 64,218 |
| Feb 23, 2026 | William D. Turnerofficer: Chief Regulatory Officer | Sale | 2,187 | $41.98 | 45,313 |
| Feb 23, 2026 | David Lee Johnsonofficer: Chief Operating Officer | Sale | 2,579 | $41.98 | 45,727 |
| Feb 23, 2026 | Marshall Fordycedirector, officer: PRESIDENT AND CEO | Sale | 16,925 | $41.98 | 257,163 |
| Feb 23, 2026 | Sean Grantofficer: CHIEF FINANCIAL OFFICER | Sale | 4,949 | $41.98 | 114,181 |
| Feb 23, 2026 | Joseph R. Youngofficer: SVP, FINANCE, CHIEF ACCT OFFCR | Sale | 3,117 | $41.98 | 64,722 |
CongressHouse and Senate disclosures
Not reported.